-
Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanc HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hummi...资讯2026-01-06
最热
推荐
- 普惠金融推进月 农发行常德市分行在行动
- 2025中国上海国际童书展圆满落幕 全球儿童内容产业在沪呈现蓬勃活力
- 数智医疗创新共同体和成都高新区数智医疗创新联盟成立,成都高新区数智医疗产业再添新活力
- Investing in child protection could save world economy $7 trillion a year, says new campaign ahead o
- PicSee推出全球首个可从好友处获取自身所有照片的社交平台
- Amlan International Highlights Holistic Gut Health Solutions and Sponsors Media Room at World Dairy
- 从噪音战场到治愈空间:她家的厨房偷偷升级了
- 滔搏斩获 “鼎新杯” 优秀案例,引入嘉为蓝鲸打造智能运维平台
- 小柯剧场中国的“百老汇” 打破经营模式 迎来全产业文化输出
- 阳光人寿荣获2024“年度卓越人寿保险公司”奖项
